The latest news updates from the 2024 Symposium
Per Hall, MD, PhD, discusses a Friday afternoon presentation on the KARISMA-2 low dose tamoxifen trial.
Hans-Christian Kolberg, MD, PhD, discusses a Friday morning poster presentation analyzing the neoadjuvant neoMono trial.
Sacha Howell, PhD, FRCP, and Angel Guerrero-Zotano, MD, PhD, discuss their Friday morning poster presentations.
Malcolm Bevel, PhD, MSPH; Richard J. Bleicher, MD, FACS; and Marcela Mazo-Canola, MD, discuss their Friday morning poster presentations.
Frederick Howard, MD, discusses a Thursday afternoon presentation on whether inflammatory breast cancer is a genomically different type of breast cancer.
Carsten F.J. Bakhuis discusses a Thursday evening poster presentation on worse prognosis for breast cancer in the second and third trimesters of pregnancy and shortly postpartum.
Neelima Vidula, MD, discusses a Thursday evening poster presentation on immune related adverse events in patients over 65 years of age vs. those younger than 65 years with breast cancer who were treated with immunotherapy.
Erika Hamilton, MD, discusses a Thursday evening poster presentation on the activity of ARV-471 in combination with a CDK4/6 inhibitor in patients with HR+ metastatic breast cancer.
Mikael Eriksson, PhD, and Kelly-Anne Phillips, MBBS, MD, FRACP, discuss their Thursday morning poster presentations.
Barbara Pistilli, MD, discusses a Thursday morning poster presentation analyzing the CAPItello-292 Phase 1b trial.